Search Results

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced new data from a study further confirming the performance of its DecisionDx-UM test as a robust independent predictor of metastasis-free survival in patients diagnosed with UM.

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in high-risk blood cancer patients, at the 65th American Society of Hematology Annual Meeting & Exposition (ASH), taking place December 9-12, 2023, in San Diego, California.

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2).

uMed, the health and research technology company, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has selected its service to support the global expansion of its wide-scale study exploring the link between loss of smell and brain disease.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6.

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today positive results from 50 patients in two multi-center Phase 2 trials for UM171 cell therapy conducted at transplant centers in the U.S., Canada and Europe, building on prior strong data from a Phase 1/2 trial and comparative registry studies (CIBMTR and EBMT).

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of a study completed in collaboration with the Melanoma Research Foundation (MRF) in which most patients diagnosed with uveal melanoma (UM) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their UM tumor was at a high or low risk of metastasis.

ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced findings from a study that evaluated uveal melanoma (UM) patients’ attitudes toward prognostic testing and specifically with respect to DecisionDx-UM®.

Castle Biosciences, Inc. announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.